In line with this, ruxolitinib treatment of non-tumour-bearing mice skewed the pattern of NK-cell maturation defined by CD11b and CD27 expression38, 39 (Fig. 5a), and reduced the percentage of NK cells expressing the maturation markers DNAM1 and KLGR1 (Fig. 5b,c). This evidence concerns the gene CD226 and neoplasm.